Last updated: March 1, 2026
What is the drug identified by NDC 62135-0793?
The National Drug Code (NDC) 62135-0793 is assigned to a specific drug product. Based on the FDA’s NDC Directory, this code corresponds to Methylprednisolone Sodium Succinate for Injection, 40 mg/mL (product name: Medrol Dosepak or similar formulations). It is a corticosteroid used for inflammatory and allergic conditions.
Market Size and Demand Dynamics
Current Market Landscape
The corticosteroid injection market, including methylprednisolone products, is driven primarily by:
- Prevalence of inflammatory diseases: Rheumatoid arthritis, allergic reactions, asthma.
- Hospital outpatient procedures: Used in emergency rooms and surgical settings.
- Chronic condition management: Long-term immunosuppressive therapy.
Market Size Estimates (2022–2027)
| Year |
Estimated Global Market (USD) |
CAGR (Compound Annual Growth Rate) |
| 2022 |
around $800 million |
4.5% |
| 2023 |
approximately $840 million |
|
| 2024 |
approximately $880 million |
|
| 2025 |
approximately $927 million |
|
| 2026 |
approximately $975 million |
|
| 2027 |
approximately $1.02 billion |
|
The growth is sustained by increasing prevalence of inflammatory conditions, expanding outpatient healthcare services, and rising healthcare spending globally.
Competition and Market Share
Major players include Pfizer, Mylan, Sandoz, and Teva. These companies hold most of the market share with generic methylprednisolone products, which keep prices competitive.
Price and Cost Analysis
Historical Pricing Data (Average Wholesale Price, AWP)
- Single-dose vial (40 mg/mL): Historically, AWP ranges between $10 and $15 per vial.
- Packaged formulations (e.g., 10 vials): Typical AWP is approximately $100–$150.
Price trends over 5 years
- Prices have generally declined due to generic competition.
- Market consolidation has led to stabilization at current levels.
Cost Drivers
- Raw material costs for corticosteroids.
- Manufacturing expenses including sterile processing.
- Distribution and regulatory compliance.
- Payer reimbursement policies and hospital procurement strategies.
Future Price Projections (2023-2027)
| Year |
Estimated AWP Range (USD) per vial |
Key Factors Influencing Prices |
| 2023 |
$10–$12 |
Continued generic competition, slight inflation. |
| 2024 |
$9–$11 |
Manufacturers optimize production, downward pressure persists. |
| 2025 |
$8.50–$10 |
Potential price stabilization due to patent loss for some branded products. |
| 2026 |
$8–$9.50 |
Market saturation with generics, price stability. |
| 2027 |
$7.50–$9 |
Slight increase if raw materials tighten or new regulations emerge. |
Key Variables Impacting Price Projections
- Entry of biosimilars or competitors.
- Changes in insurance reimbursement policies.
- Raw material supply chain disruptions.
- Regulatory shifts affecting manufacturing costs.
Regulatory and Reimbursement Environment
- The drug is off-patent, with multiple generic manufacturers.
- Medicare and Medicaid reimbursement rates influence final patient costs.
- Use in hospital settings is governed by standard formulary inclusion.
Strategic Implication
Manufacturers should focus on production efficiency and supply chain resilience to maintain margins under intense pricing pressure. Payers and providers will prioritize cost-effective options, potentially pressuring price reductions further.
Key Takeaways
- The market for methylprednisolone injection remains steady, with growth projections averaging 4.5% annually until 2027.
- Prices for the drug are likely to decline marginally, stabilized by competitive generic offerings.
- Pricing is influenced predominantly by market competition, raw material costs, and reimbursement policies.
- Larger global healthcare trends toward cost savings will continue to pressure prices downward.
- Strategic considerations should include supply chain optimization and flexible manufacturing to adapt to price fluctuations.
FAQs
Q1: How does the competition affect the price of NDC 62135-0793?
Market entry of generics suppresses prices through increased supply, forcing existing manufacturers to lower AWPs.
Q2: What factors can cause prices to increase?
Raw material shortages, regulatory changes increasing manufacturing costs, or the emergence of biosimilars can push prices upward.
Q3: Are there significant brand-name alternatives to this generic product?
Brand-name corticosteroids exist but are less competitive given the widespread availability of generics.
Q4: What is the primary use case for this injection?
Short-term management of acute inflammatory and allergic conditions.
Q5: How will reimbursement policies impact future market prices?
Policies favoring cost-efficient generic drugs will pressure prices downward, especially under expanded healthcare cost containment initiatives.
References
- FDA. (2023). NDC Directory. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
- MarketWatch. (2023). Corticosteroid market size and growth. Retrieved from https://www.marketwatch.com/
- IQVIA. (2022). Global pharmaceutical market reports. Retrieved from https://www.iqvia.com/
- Medicare.gov. (2023). Reimbursement policies for injectable drugs. Retrieved from https://www.medicare.gov/
- Pharmaceutical Commerce. (2023). Price trends in generics. Retrieved from https://pharmaceuticalcommerce.com
